Serum concentrations of the thyroid hormone binding proteins, thyroxine binding globulin, prealbumin, and albumin were determined in 30 thyrotoxic patients before and after 1a11 treatment. Each patient was placed into one of three groups according to response to treatment. The serum concentration of all three proteins rose significantly in 10 patients who became euthyroid, and a greater increase was seen in 10 patients who developed hypothyroidism. There was no significant change in thyroid hormone binding protein concentrations in 10 subjects who remained hyperthyroid. Changes in the concentration of thyroid hormone binding proteins should be borne in mind when total thyroid hormone concentrations are used to monitor the progress of patients receiving treatment for hyperthyroidism.
The thyroid hormone binding proteins (THBP), thyroxine-binding globulin (TBG), prealbumin (PA), and albumin, transport over 99 % of the circulating thyroxine (T 4 ) and triiodothyronine (T a). These proteins are synthesised in the liver. The permissive physiological role of thyroid hormones on protein synthesis is well known,' but hyperthyroidism is characterised by enhanced protein catabolism and a negative nitrogen balance. Furthermore, normal subjects given thyroid hormone sufficient to render them hyperthyroid show a tendency to hypoproteinaemia affecting both albumin and globulin fractions.s This fall in the concentration of plasma proteins appears to extend to the THBP; several earlier studies have reported a reduction in the thyroxine-binding capacity of TBG and PA in hyperthyroidism,a-s which revert to normal after successful treatment." Specific and direct assays for TBG and PA now exist, and we here describe serum concentrations of THBP in hyperthyroid subjects. We have also examined the changes in the concentrations of these proteins that occur after radioiodine treatment for hyperthyroidism.
Patients and methods
Blood was taken from 30 newly diagnosed, ambulant, thyrotoxic patients. Serum samples were stored at -20 o C, and samples from each patient were assayed in the same batch. TBG7 and PA were measured by 'rocket' immunoelectrophoresis, using antisera supplied by Seward Laboratory, Inverhorne Lane, East Grinstead, Sussex. Serum standards for TBG and PA, based on British Standard 74/520, were also obtained from Seward Laboratory. Albumin was measured by the bromocresol green method. Mean interassay coefficients of variation at low, medium, and high levels ofTBG, PA, and albumin were 3'1 %, 5'0%, and 1'9%, respectively. Serum T 4 concentration was measured by radioimmunoassay using polyethylene glycol separation and serum Ta and TSH by kit methods (Ta-Radiochemical Centre, Amersham; TSH-Immophase, Corning Medical, Halstead, Essex). Statistical calculations were performed using Student's f test.
Results
The patients were divided into three groups of 10 according to the clinical and biochemical response of each subject to radioiodine therapy. Patients in group 1 remained thyrotoxic at three and six months and were then given further antithyroid treatment. Patients in group 2 were clinically and biochemically euthyroid when assessed at 18 and 24 months, and group 3 comprised patients who became hypothyroid during the six-month period following treatment and who then started thyroxine replacement therapy.
SER UM THBP CONCENTRA nONS IN THYROTOXIC PATIENTS
The results of serum TBG, PA, and albumin determinations in the 30 thyrotoxic patients are 211 183 ± 16 mg/l ; albumin 46'2 ± 1'1 g/I v. 45·5 ± 0·9 g/I). In those patients who became hypothyroid over this period (group 3), serum TBG, PA, and albumin concentrations rose to levels at six months which were significantly higher than the pretreatment levels (TBG 15·3 ± 1·0 mg/I v. 10·0 ± shown in Figure 1 . Serum TBG concentrations were slightly lower (10'9 ± 0·6 mg/l; mean ± SEM) than in 30 healthy euthyroid subjects (11'4 ± O' 6 rng/l), but the difference was not statistically significant. There was no difference between the serum albumin concentrations of the thyrotoxic patients (43'6 ± 1'4 g/I) and of the euthyroid subjects (44'3 ± 0·5 gJl) although the scatter of results was wider in the thyrotoxic group. Serum PA concentrations, however, were much lower 
Results expressed as mcao±SEM.
0·6 mg/l; PA 307 ± 17 mg!l v. 192 ± 19 mg/I; albumin 50·2 ± 1·6 g/I v. 43·2 ± 2·2 g/l). Ten patients in group 2 were euthyroid 18 and 24 months after treatment and had normal serum T 4 , T 3' and TSH concentrations at both these times; euthyroid status in these patients could therefore be regarded as stable. Serum TBG, PA, and albumin concentrations in the group 2 patients at 24 months were significantly higher than pretreatment concentrations (TBG 12·2 ± 0·7 mg/I v. 10·4 ± 0·3 mg/l; PA 261 ± 31 mg/l v. 180 ± 20 mg/I; albumin 46·2 ± 1·2 g/I v. 42·2 ± 0·6 g/!).
Discussion
Most earlier reports of serum THBP concentrations in thyroid disease, using electrophoretic techniques assessing maximum binding capacities, have shown reduced levels of serum TBG and PA in hyperthyroidism. The specific measurement of serum TBG by immunoassay in hyperthyroid subjects has given both normal'r'! and lows 12 13 levels. Both norrnal'f and IOW 15 16 TBG concentrations as measured by competitive ligand-binding assays have also been described in hyperthyroidism. Some of these differences may stem from a failure to allow for sexand age-related differences in serum TBG concentration, and also for the possibility of slightly higher concentrations of TBG in mildly hyperthyroid subjects.l" Furthermore, as our data illustrate, significant changes may occur without the level falling outside the 'normal' range.
The results of our longitudinal study show that the serum concentrations of THBP increase with successful treatment of hyperthyroidism; a further rise is seen if hypothyroidism ensues. The greatest changes occur in serum PA concentrations. As similar trends occur in the concentration of all three binding proteins, however, it seems most likely that the differences are a reflection of changes in protein turnover. Refetoff et al. IS found that the half-life of TBG was markedly reduced to 3· 6 days in two patients with hyperthyroidism, compared with a mean value of 5·3 days in euthyroid subjects. The concentrations of specific proteins other than THBP may also be reduced in hyperthyroidism. These include enzyrnes'" and myoglobin.F Although some of the changes could reflect the presence of thyrotoxic myopathy." the fall in serum creatine kinase activity in hyperthyroidism appears to be due, in part at least, to an increase in disappearance rate of the enzyme.F Such findings further suggest that the fall in THBP concentrations is a result of hypercatabolism caused by increased thyroid hormone production.
The differences in specific plasma protein concentrations occurring in hyperthyroidism could be related to differences in plasma volume, which increases by about 10% with the development of hyperthyroidism." This is insufficient, however, to be the sole explanation of the considerable changes in serum THBP concentrations that we have observed.
For any given hormone level, the unbound fraction will rise as the concentration of binding proteins falls. Accurate biochemical assessment of the severity of hyperthyroidism should therefore include some form of assessment of THBP concentration. One should also be aware of the considerable changes that occur in THBP concentrations should measurements of total thyroid hormone concentrations be used to monitor the treatment of hyperthyroidism.
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